Inventor · disambiguated record
Daniel R. Henderson
Also filed as: HENDERSON DANIEL R · HENDERSON DANIEL ROBERT
36 granted patents·19 pending applications·1,547 citations·filing 1985–2024
98Inventor score
Top patents by PatentIndex Score
55 records- 0196US7968333B2Adenovirus vectors containing cell status-specific response elements and methods of use thereofCOLD GENESYS INC·Filed 2007·Granted Jun 28, 2011·62 cites·5 claims
- 0296US6692736B2Cell-specific adenovirus vectors comprising an internal ribosome entry siteCELL GENESYS INC·Filed 2001·Granted Feb 17, 2004·129 cites·41 claims
- 0396US6436394B1Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereofCELL GENESYS INC·Filed 2000·Granted Aug 20, 2002·90 cites·26 claims
- 0494US5698443ATissue specific viral vectorsCALYDON INC·Filed 1995·Granted Dec 16, 1997·139 cites·12 claims
- 0593US4708929AMethods for protein binding enzyme complementation assaysMICROGENICS CORP·Filed 1985·Granted Nov 24, 1987·127 cites·4 claims
- 0692US6916918B2Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereofCELL GENESYS INC·Filed 2001·Granted Jul 12, 2005·32 cites·14 claims
- 0792US6911200B2Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiationCELL GENESYS INC·Filed 2001·Granted Jun 28, 2005·30 cites·9 claims
- 0892US6585968B2Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereofCELL GENESYS INC·Filed 2001·Granted Jul 1, 2003·36 cites·22 claims
- 0992US5648478ATissue-specific enhancer active in prostateFiled 1995·Granted Jul 15, 1997·76 cites·5 claims
- 1091US5871726ATissue specific and tumor growth supperssion by adenovirus comprising prostate specific antigenCALYDON INC·Filed 1996·Granted Feb 16, 1999·100 cites·32 claims
- 1190US6676935B2Tissue specific adenoviral vectorsCELL GENESYS INC·Filed 1998·Granted Jan 13, 2004·102 cites·31 claims
- 1289USRE42373EAdenovirus vectors containing cell status-specific response elements and methods of use thereofCOLD GENESYS INC·Filed 2008·Granted May 17, 2011·4 cites·31 claims
- 1389US7575919B2Adenovirus vectors containing cell status-specific response elements and methods of use thereofCELL GENESYS INC·Filed 2004·Granted Aug 18, 2009·11 cites·9 claims
- 1489US6991935B2Target cell-specific adenoviral vectors containing E3 and methods of use thereofCELL GENESYS INC·Filed 2002·Granted Jan 31, 2006·16 cites·19 claims
- 1588US6197293B1Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereofCALYDON INC·Filed 1998·Granted Mar 6, 2001·54 cites·54 claims
- 1687US6852528B2Human and mouse uroplakin II gene transcriptional regulatory elementsCELL GENESYS INC·Filed 2001·Granted Feb 8, 2005·26 cites·27 claims
- 1786US10022436B2Microneedle compositions and methods of using sameVERNDARI INC·Filed 2017·Granted Jul 17, 2018·3 cites·27 claims
- 1885US7001764B2Compositions comprising tissue specific adenoviral vectorsCELL GENESYS INC·Filed 2002·Granted Feb 21, 2006·14 cites·21 claims
- 1985US5830686ATissue-specific enhancer active in prostateCALYDON·Filed 1994·Granted Nov 3, 1998·44 cites·1 claims
- 2084US7276233B2Methods of treating neoplasia with combinations of target cell-specific adenovirus and chemotherapyCELL GENESYS INC·Filed 2005·Granted Oct 2, 2007·2 cites·4 claims
- 2184US6495130B1Target cell-specific adenoviral vectors containing E3 and methods of use thereofCALYDON INC·Filed 1999·Granted Dec 17, 2002·54 cites·15 claims
- 2284US5604091AMethods for protein binding enzyme complementationMICROGENICS CORP·Filed 1994·Granted Feb 18, 1997·52 cites·12 claims
- 2383US6432700B1Adenovirus vectors containing heterologous transcription regulatory elements and methods of using sameCELL GENESYS INC·Filed 1998·Granted Aug 13, 2002·65 cites·17 claims
- 2482US6254862B1Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereofCALYDON INC·Filed 1998·Granted Jul 3, 2001·48 cites·63 claims
- 2581US5643734AMethods for protein binding enzyme complementation assaysMICROGENICS CORP·Filed 1995·Granted Jul 1, 1997·59 cites·6 claims
- 2681US5120653AVector comprising DNA sequence coding for enzyme-donor polypeptideMICROGENICS CORP·Filed 1985·Granted Jun 9, 1992·40 cites·4 claims
- 2780US7319033B2Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereofCELL GENESYS INC·Filed 2002·Granted Jan 15, 2008·9 cites·19 claims
- 2880US6900049B2Adenovirus vectors containing cell status-specific response elements and methods of use thereofCELL GENESYS INC·Filed 1999·Granted May 31, 2005·26 cites·31 claims
- 2979US2025083117A1Microarrays and methodsVERNDARI INC·Filed 2024·Application pending·0 cites
- 3078US6057299ATissue-specific enhancer active in prostateCALYDON INC·Filed 1996·Granted May 2, 2000·47 cites·34 claims
- 3170US6136792AProstate specific enhancer polynucleotides and methods of use thereofCALYDON INC·Filed 1997·Granted Oct 24, 2000·18 cites·18 claims
- 3268US2008076173A1Adenovirus vectors containing cell status-specific response elements and methods of use thereofCELL GENESYS INC·Filed 2007·Application pending·0 cites
- 3368US2008171390A1Adenovirus vectors containing cell status-specific response elements and methods of use thereofCELL GENESYS INC·Filed 2007·Application pending·0 cites
- 3468US2008166797A1Adenovirus vectors containing cell status-specific response elements and methods of use thereofCELL GENESYS INC·Filed 2007·Application pending·0 cites
- 3567US2006188479A1Adenovirus vectors containing cell status-specific response elements and methods of use thereofYU DE C·Filed 2005·Application pending·0 cites
- 3665US2023000974A1Virus-like particle vaccinesVERNDARI INC·Filed 2022·Application pending·0 cites
- 3763US10363303B2Microneedle compositions and methods of using sameVERNDARI INC·Filed 2018·Granted Jul 30, 2019·0 cites·20 claims
- 3863US2009297483A1Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereofCELL GENESYS INC·Filed 2007·Application pending·0 cites
- 3962US2008247996A1Methods of treating neoplasia with combination target cell-specific adenovirus, chemotherapy and radiationCELL GENESYS INC·Filed 2007·Application pending·0 cites
- 4060US2025134986A1Stabilized lipid nanoparticle mrna compositions and uses thereofVERNDARI INC·Filed 2022·Application pending·0 cites
- 4159US2004241857A1Tissue specific adenoviral vectorsFiled 2004·Application pending·0 cites
- 4258US2022280633A1Virus-like particle vaccinesVERNDARI INC·Filed 2020·Application pending·0 cites
- 4356US6406861B1Methods of enhancing effectiveness of therapeutic viral immunogenic agent administrationCELL GENESYS INC·Filed 1999·Granted Jun 18, 2002·12 cites·26 claims
- 4456US2004146489A1Cell-specific adenovirus vectors comprising an internal ribosome entry siteFiled 2003·Application pending·0 cites
- 4555US2005036951A1Methods of treating lung diseasesARIZEKE PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 4654US2019184366A1Microarrays and methodsVERNDARI INC·Filed 2017·Application pending·0 cites
- 4751US2002198164A1Tissue-specific enhancer active in prostateFiled 2001·Application pending·0 cites
- 4850US2002068049A1Tissue specific adenoviral vectorsFiled 2000·Application pending·0 cites
- 4948US6673614B2Rapid methods and kits for detection and semi-quantitation of anti-adenovirus antibodyCELL GENESYS INC·Filed 2001·Granted Jan 6, 2004·7 cites·16 claims
- 5045US2006024273A1Target cell-specific adenoviral vectors containing E3 and methods of use thereofHENDERSON DANIEL R·Filed 2005·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →